(Tromsø 8. May 2017) Stuart Devine, VP Marketing in Biotec Betaglucans AS has
today purchased 20.000 shares in Biotec Pharmacon at NOK 6,14 per share. After
this transaction, Stuart Devine and associates hold 45.187 shares and 30.000
options in Biotec Pharmacon.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
For further information, please contact
Børge Sørvoll
CFO
+47 952 90 187
borge.sorvoll@biotec.no

